Literature DB >> 22085171

Salmonella expressing detoxified lipopolysaccharide is immunogenic and protective both as an attenuated vaccine and for delivery of foreign antigens.

James E Galen1, Raphael Simon, Robert K Ernst.   

Abstract

The construction of safe and protective vaccines, derived from human pathogens that have been genetically modified to remove pathogenicity, is often easier to accomplish on paper than it is in the laboratory. Kong and colleagues have pursued a clever strategy to reduce the reactogenicity of attenuated Salmonella oral vaccines by genetically modifying the surface lipopolysaccharide to lower endotoxic activity. The resulting candidate vaccine strains were highly reduced in virulence yet were able to confer protection in a mouse model against challenge with virulent Salmonella. Remarkably, these strains could also be further modified to present foreign antigens from unrelated human pathogens and again confer protection against heterologous challenge. This work brings important new tools to bear on solving the problem of creating efficacious attenuated bacterial vaccines that maximize both safety and immunogenicity in clinical trials.

Entities:  

Year:  2011        PMID: 22085171      PMCID: PMC3289411          DOI: 10.1586/erv.11.155

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  15 in total

1.  Phase I clinical trials of aroA aroD and aroA aroD htrA attenuated S. typhi vaccines; effect of formulation on safety and immunogenicity.

Authors:  D A Dilts; I Riesenfeld-Orn; J P Fulginiti; E Ekwall; C Granert; J Nonenmacher; R N Brey; S J Cryz; K Karlsson; K Bergman; T Thompson; B Hu; A H Brückner; A A Lindberg
Journal:  Vaccine       Date:  2000-02-14       Impact factor: 3.641

2.  Salmonella synthesizing 1-dephosphorylated [corrected] lipopolysaccharide exhibits low endotoxic activity while retaining its immunogenicity.

Authors:  Qingke Kong; David A Six; Kenneth L Roland; Qing Liu; Lillian Gu; C Michael Reynolds; Xiaoyuan Wang; Christian R H Raetz; Roy Curtiss
Journal:  J Immunol       Date:  2011-06-01       Impact factor: 5.422

Review 3.  The safety evaluation of adjuvants during vaccine development: the AS04 experience.

Authors:  Nathalie Garçon; Lawrence Segal; Fernanda Tavares; Marcelle Van Mechelen
Journal:  Vaccine       Date:  2011-04-27       Impact factor: 3.641

4.  Salmonella vaccine vectors displaying delayed antigen synthesis in vivo to enhance immunogenicity.

Authors:  Shifeng Wang; Yuhua Li; Giorgio Scarpellini; Wei Kong; HuoYing Shi; Chang-Ho Baek; Bronwyn Gunn; Soo-Young Wanda; Kenneth L Roland; Xin Zhang; Patti Senechal-Willis; Roy Curtiss
Journal:  Infect Immun       Date:  2010-07-06       Impact factor: 3.441

5.  phoP/phoQ-deleted Salmonella typhi (Ty800) is a safe and immunogenic single-dose typhoid fever vaccine in volunteers.

Authors:  E L Hohmann; C A Oletta; K P Killeen; S I Miller
Journal:  J Infect Dis       Date:  1996-06       Impact factor: 5.226

6.  Evaluation of a phoP/phoQ-deleted, aroA-deleted live oral Salmonella typhi vaccine strain in human volunteers.

Authors:  E L Hohmann; C A Oletta; S I Miller
Journal:  Vaccine       Date:  1996-01       Impact factor: 3.641

7.  AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity.

Authors:  Arnaud M Didierlaurent; Sandra Morel; Laurence Lockman; Sandra L Giannini; Michel Bisteau; Harald Carlsen; Anders Kielland; Olivier Vosters; Nathalie Vanderheyde; Francesca Schiavetti; Daniel Larocque; Marcelle Van Mechelen; Nathalie Garçon
Journal:  J Immunol       Date:  2009-10-28       Impact factor: 5.422

8.  Safety, infectivity, immunogenicity, and in vivo stability of two attenuated auxotrophic mutant strains of Salmonella typhi, 541Ty and 543Ty, as live oral vaccines in humans.

Authors:  M M Levine; D Herrington; J R Murphy; J G Morris; G Losonsky; B Tall; A A Lindberg; S Svenson; S Baqar; M F Edwards
Journal:  J Clin Invest       Date:  1987-03       Impact factor: 14.808

9.  Essential role of MD-2 in LPS responsiveness and TLR4 distribution.

Authors:  Yoshinori Nagai; Sachiko Akashi; Masakazu Nagafuku; Masato Ogata; Yoichiro Iwakura; Shizuo Akira; Toshio Kitamura; Atsushi Kosugi; Masao Kimoto; Kensuke Miyake
Journal:  Nat Immunol       Date:  2002-06-10       Impact factor: 25.606

10.  Evaluation of new generation Salmonella enterica serovar Typhimurium vaccines with regulated delayed attenuation to induce immune responses against PspA.

Authors:  Yuhua Li; Shifeng Wang; Giorgio Scarpellini; Bronwyn Gunn; Wei Xin; Soo-Young Wanda; Kenneth L Roland; Roy Curtiss
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-29       Impact factor: 11.205

View more
  4 in total

Review 1.  New technologies in developing recombinant attenuated Salmonella vaccine vectors.

Authors:  Shifeng Wang; Qingke Kong; Roy Curtiss
Journal:  Microb Pathog       Date:  2012-11-08       Impact factor: 3.738

Review 2.  Salmonella as a vaccine delivery vehicle.

Authors:  Kenneth L Roland; Karen E Brenneman
Journal:  Expert Rev Vaccines       Date:  2013-09       Impact factor: 5.217

Review 3.  Vaccines: from empirical development to rational design.

Authors:  Christine Rueckert; Carlos A Guzmán
Journal:  PLoS Pathog       Date:  2012-11-08       Impact factor: 6.823

Review 4.  Vaccines against invasive Salmonella disease: current status and future directions.

Authors:  Calman A MacLennan; Laura B Martin; Francesca Micoli
Journal:  Hum Vaccin Immunother       Date:  2014-05-07       Impact factor: 3.452

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.